Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 21 Neoplasms 16 Neuroblastoma 14 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 12 Fallopian Tube Neoplasms 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Lung Neoplasms 10 Recurrence 8 Leukemia 8 Leukemia, Myeloid, Acute 7 Uterine Cervical Neoplasms 6 Unspecified Adult Solid Tumor, Protocol Specific 6 Neoplasm Metastasis 6 Lymphoma 6 Sarcoma, Ewing 5 Endometrial Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 5 Sarcoma 4 Lymphoma, Follicular 4 Glioma 4 Central Nervous System Neoplasms 4 Burkitt Lymphoma 4 Blast Crisis 4 Rhabdomyosarcoma 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Myelodysplastic Syndromes 3 Meningeal Carcinomatosis 3 Medulloblastoma 3

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Malignant Disease × Topotecan × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡